Table 2.
Antibody signals to historically identified non-α-Gal carbohydrate antigens in pre-transplant NHPs
| IgM signal |
IgG signal |
|||||||
|---|---|---|---|---|---|---|---|---|
| a411 print # | Abbreviation | Description | Prototypic xenoantigen | Biological relevance | Median | SD | Median | SD |
| 159 | Ac-TF(Ser)-G - 24 | Ac-(Galb1–3GalNAca)Ser-Gly-Hex-BSA | Galβ1–3GalNAc [11] | possible [29] | 15.81 | 0.22 | 11.75 | 0.31 |
| 128 | Ac-S-TF(Ser)-S-G - 28 | Ac-Ser-(Galb1–3GalNAca)Ser-Ser-Gly-Hex-BSA | Galβ1–3GalNAc [11] | possible [29] | 15.50 | 0.34 | 11.58 | 0.47 |
| 109 | Ac-S-TF(Ser)-S-G - 16 | Ac-Ser-(Galb1–3GalNAca)Ser-Ser-Gly-Hex-BSA | Galβ1–3GalNAc [11] | possible [29] | 15.14 | 0.42 | 11.19 | 0.56 |
| 22 | GA1di −11 | Galb1–3GalNAcb – HSA | Galβ1–3GalNAc [11] | possible [30, 31] | 14.63 | 0.35 | 10.88 | 0.91 |
| 312 | GM2-Sp - 07 | Neu5Aca2–3[GalNAcb1–4]Galb1–4Glcb-Sp-BSA | Sda epitope [8] | strong [32] | 14.09 | 1.65 | 10.18 | 1.32 |
| 274 | 6’Neu5Ac-LDN-Sp - 13 | Neu5Aca2–6GalNAcb1–4GlcNAcb-Sp-BSA | Siaα2–6Gal/GalNAc [11] | weak [33] | 13.70 | 0.70 | 9.55 | 1.17 |
| 96 | GM2-Sp - 14 | Neu5Aca2–3[GalNAcb1–4]Galb1–4Glcb-Sp-BSA | Sda epitope [8] | strong [32] | 13.61 | 1.65 | 9.40 | 0.99 |
| 241 | SSEA-4-Sp - 12 | Neu5Aca2–3Galb1–3GalNAcb1–3Gala1–4Galb1–4Glcb-Sp-BSA | Galβ1–3GalNAc [11] | strong [34] | 13.50 | 2.32 | 9.52 | 1.73 |
| 57 | GA1 – 20 | Galb1–3GalNAcb1–4Galb1-BSA | Galβ1–3GalNAc [11] | possible [30, 31] | 13.35 | 1.01 | 10.33 | 1.14 |
| 80 | P1 – 09 | Gala1–4Galb1–4GlcNAc-BSA | P1 [6] | strong [6] | 13.23 | 1.02 | 9.08 | 1.07 |
| 118 | GA1 – 06 | Galb1–3GalNAcb1–4Galb1-BSA | Galβ1–3GalNAc [11] | possible [30, 31] | 13.21 | 0.77 | 9.11 | 1.00 |
| 158 | Ac-TF(Ser)-G - 04 | Ac-(Galb1–3GalNAca)Ser-Gly-Hex-BSA | Galβ1–3GalNAc [11] | possible [29] | 12.98 | 0.52 | 9.55 | 0.52 |
| 139 | BG-H2– 12 | Fuca1–2Galb1–4GlcNAcb1-linker-BSA | terminal H type2 [6] | strong [6] | 12.68 | 1.25 | 8.82 | 0.95 |
| 305 | Gb5/SSEA3 – 12 | Galb1–3GalNAcb1–3Gala1–4Galb1-BSA | Galβ1–3GalNAc [11] | possible [35] | 12.65 | 1.61 | 8.89 | 1.10 |
| 288 | GT2-Sp - 08 | Neu5Aca2–8Neu5Aca2–8Neu5Aca2–3[GalNAcb1–4]Galb1–4Glcb-Sp-BSA | Sda epitope [8] | strong [36] | 12.47 | 1.05 | 9.01 | 1.48 |
| 246 | BG-H2 – 16 | Fuca1–2Galb1–4GlcNAcb-HSA | terminal H type2 [6] | strong [6] | 12.44 | 1.29 | 8.07 | 0.79 |
| 231 | SSEA-4-Sp - 05 | Neu5Aca2–3Galb1–3GalNAcb1–3Gala1–4Galb1–4Glcb-Sp-BSA | Galβ1–3GalNAc [11] | strong [34] | 12.41 | 2.14 | 8.75 | 1.35 |
| 123 | Ac-S-TF(Ser)-S-G - 04 | Ac-Ser-(Galb1–3GalNAca)Ser-Ser-Gly-Hex-BSA | Galβ1–3GalNAc [11] | possible [29] | 12.35 | 1.01 | 8.21 | 0.83 |
| 82 | GM1a - 29 | Galb1–3GalNAcb1–4(Neu5Aca2–3)Galb1–4(Glc)HSA | Galβ1–3GalNAc [11] | strong [32] | 12.24 | 1.01 | 9.05 | 0.57 |
| 336 | GM2-Sp - 04 | Neu5Aca2–3[GalNAcb1–4]Galb1–4Glcb-Sp-BSA | Sda epitope [8] | strong [32] | 12.14 | 1.59 | 8.37 | 1.03 |
| 330 | GD2-Sp - 10 | Neu5Aca2–8Neu5Aca2–3[GalNAcb1–4]Galb1–4Glcb-Sp-BSA | Sda epitope [8] | possible [37] | 12.09 | 1.70 | 10.26 | 1.69 |
| 280 | GQ2-Sp - 06 | Neu5Aca2–8Neu5Aca2–8Neu5Aca2–8Neu5Aca2–3[GalNAcb1–4]Galb1–4Glcb-Sp-BSA | Sda epitope [8] | NA | 12.06 | 0.80 | 8.69 | 1.41 |
| 247 | CT/Sda-Sp - 13 | Neu5Aca2–3[GalNAcb1–4]Galb1–4GlcNAcb-Sp-BSA | Sda epitope [8] | strong [8] | 11.59 | 1.10 | 9.05 | 0.93 |
| 324 | 6’Neu5Ac-LDN-Sp - 05 | Neu5Aca2–6GalNAcb1–4GlcNAcb-Sp-BSA | Siaα2–6Gal/GalNAc [11] | weak [33] | 11.58 | 1.63 | 7.69 | 1.08 |
| 47 | 6’Neu5Ac-Lac | Neu5Aca2–6Galb1–4Glc-APD-HSA | Siaα2–6Gal/GalNAc [11] | NA | 11.52 | 2.09 | 8.28 | 1.23 |
| 236 | GD1a-Sp - 10 | Neu5Aca2–3[Neu5Aca2–3Galb1–3GalNAcb1–4]Galb1–4Glcb-Sp-BSA | Sda epitope [8] | strong [38] | 11.37 | 1.55 | 7.88 | 1.14 |
| 314 | GD2-Sp - 04 | Neu5Aca2–8Neu5Aca2–3[GalNAcb1–4]Galb1–4Glcb-Sp-BSA | Sda epitope [8] | possible [37] | 11.33 | 2.24 | 9.65 | 1.68 |
| 295 | GT2-Sp - 03 | Neu5Aca2–8Neu5Aca2–8Neu5Aca2–3[GalNAcb1–4]Galb1–4Glcb-Sp-BSA | Sda epitope [8] | strong [36] | 11.10 | 1.18 | 8.25 | 1.52 |
| 186 | GTSSA-TF(Ser)-TGHATPLPVTD | BSA-PEG7-Gly-Thr-Ser-Ser-Ala-(Galb1–3GalNAca)Ser-Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp | Galβ1–3GalNAc [11] | possible [29] | 11.03 | 1.37 | 7.92 | 0.50 |
| 304 | GQ2-Sp - 03 | Neu5Aca2–8Neu5Aca2–8Neu5Aca2–8Neu5Aca2–3[GalNAcb1–4]Galb1–4Glcb-Sp-BSA | Sda epitope [8] | NA | 11.02 | 1.37 | 7.85 | 1.54 |
| 138 | BG-H2– 06 | Fuca1–2Galb1–4GlcNAcb1-linker-BSA | terminal H type2 [6] | strong [6] | 10.92 | 0.72 | 8.37 | 0.53 |
| 291 | Gb5/SSEA3 – 04 | Galb1–3GalNAcb1–3Gala1–4Galb1-BSA | Galβ1–3GalNAc [11] | possible [35] | 10.49 | 2.08 | 7.43 | 1.07 |
| 135 | LNnT - 04 | Galb1–4GlcNAcb1–3Galb1-BSA | uncapped LacNAc [6] | strong [6] | 10.47 | 0.84 | 8.13 | 0.77 |
| 229 | GD1a-Sp - 05 | Neu5Aca2–3[Neu5Aca2–3Galb1–3GalNAcb1–4]Galb1–4Glcb-Sp-BSA | Galβ1–3GalNAc [11] | strong [32] | 10.44 | 2.03 | 7.26 | 0.92 |
| 319 | 6’Neu5Ac-LacNAc-Sp - 11 | Neu5Aca2–6Galb1–4GlcNAcb-Sp-BSA | Siaα2–6Gal/GalNAc [11] | NA | 10.37 | 1.18 | 7.52 | 0.15 |
| 298 | CT/Sda-Sp - 05 | Neu5Aca2–3[GalNAcb1–4]Galb1–4GlcNAcb-Sp-BSA | Sda epitope [8] | strong [8] | 10.31 | 1.33 | 7.68 | 0.50 |
| 162 | NGA2 – 07 | GlcNAcb1–2Mana1–6(GlcNAcb1–2Mana1–3)Manb1–4GlcNAc -BSA | ion 1851.7 [10] | strong [10] | 10.14 | 0.60 | 7.47 | 0.24 |
| 187 | GTSSAS-TF(Thr)-GHATPLPVTD | BSA-PEG7-Gly-Thr-Ser-Ser-Ala-Ser-(Galb1–3GalNAca)Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp | Galβ1–3GalNAc [11] | possible [29] | 10.05 | 0.89 | 7.99 | 0.39 |
| 261 | 6’Neu5Ac-LacNAc-Sp - 05 | Neu5Aca2–6Galb1–4GlcNAcb-Sp-BSA | Siaα2–6Gal/GalNAc [11] | NA | 9.64 | 0.86 | 7.38 | 0.19 |
| 311 | LacNAc (dimeric)-Sp - 06 | (Galb1–4GlcNAcb1–3)2b-Sp-BSA | uncapped LacNAc [6] | strong [6] | 9.52 | 1.40 | 7.77 | 0.62 |
| 189 | GTSSA-TF(Ser)-TF(Thr)-GHATPLPVTD | BSA-PEG7-Gly-Thr-Ser-Ser-Ala-(Galb1–3GalNAca)Ser-(Galb1–3GalNAca)Thr-Gly-His-Ala-Thr-Pro-Leu-Pro-Val-Thr-Asp | Galβ1–3GalNAc [11] | possible [29] | 9.45 | 1.47 | 7.74 | 0.53 |
| 56 | LSTc - 07 | Neu5Aca2–6Galb1–3GlcNAcb1–3Galb1-BSA | Siaα2–6Gal/GalNAc [11] | possible [39] | 9.41 | 1.23 | 7.30 | 0.15 |
| 160 | NA2 – 08 | Galb1–4GlcNAcb1–2Mana1–6[Galb1–4GlcNAcb1–2Mana1–3]Manb1–4GlcNAc -BSA | ion 2245.8 [10] | possible [10] | 8.83 | 0.73 | 7.32 | 0.17 |
| 318 | GD1b - 05 | Neu5Aca2–8Siaa2–3(Galb1–3GalNAcb1–4)Galb1–4-BSA | Galβ1–3GalNAc [11] | possible [37] | 8.27 | 1.41 | 7.80 | 0.88 |
| 188 | GTSSASTGHA-TF(Thr)-PLPVTD | BSA-PEG7-Gly-Thr-Ser-Ser-Ala-Ser-Thr-Gly-His-Ala-(Galb1–3GalNAca)Thr-Pro-Leu-Pro-Val-Thr-Asp | Galβ1–3GalNAc [11] | possible [29] | 7.71 | 0.81 | 7.23 | 0.13 |
| 230 | 6’Neu5Gc-LacNAc-Sp - 05 | Neu5Gca2–6Galb1–4GlcNAcb-Sp-BSA | Siaα2–6Gal/GalNAc [11] | NA | 7.54 | 0.42 | 7.23 | 0.00 |
| 86 | Man5 – 05 | Mana1–6(Mana1–3)Mana1–6(Mana1–3)Manb1–4GlcNAc-BSA | ion 1595.7 [10] | possible [10] | 7.23 | 0.24 | 7.23 | 0.00 |
Biological relevance is stated high when it is reported that the antigen is expressed on wild type or gene modified porcine cells/tissues. Biological relevance is stated possible when it is reported that the antigen is expressed on mammalian cells/tissues. Biological relevance is stated weak when it is reported that the antigen is not expressed on porcine cells/tissues. Numbers in brackets show reference. NA data not available, NHP nonhuman primate